Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2023-08-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
第五届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 14th meeting of the 5th Board of Directors of the company 新天地药业股份有限公司. It includes approvals of the 2023 semi-annual report and its summary, a special report on the use of raised funds, the election of a new non-independent director, change of the auditing firm, and the proposal to convene the 3rd extraordinary general meeting of shareholders in 2023. The document references other detailed reports and announcements published elsewhere (on the cninfo website) but itself is a meeting resolution announcement. It does not contain the full semi-annual report or detailed financial statements but rather the board's decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the board and management decisions. The document length is short (2111 characters), and it is not a full financial report or earnings release. Therefore, the correct classification is MANG with high confidence.
2023-08-24 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion from the independent directors regarding the company's controlling shareholders and related parties occupying company funds and external guarantees. It references regulatory guidelines and company rules, and provides an independent opinion on these matters for the reporting period ending June 30, 2023. The document is short (559 characters) and focuses on a specific governance and compliance issue rather than presenting full financial data or audit results. It is not an annual report, audit report, or financial statement. It is a standalone report related to audit and compliance matters, specifically an independent opinion on related party transactions and guarantees. Therefore, it fits best under Audit Report / Information (AR). H1 2023
2023-08-24 Chinese
2023年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2023 third extraordinary general meeting of shareholders for 新天地药业股份有限公司. It includes information about the meeting date, time, location, voting procedures (both onsite and online), registration details, agenda items (such as election of a director and change of accounting firm), and attachments like proxy forms and registration forms. There is no financial data or results reported, nor is it a transcript or presentation. It is clearly a formal announcement to shareholders about the upcoming shareholders meeting and how to participate. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2023-08-24 Chinese
2023年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 90% confidence The document is a summary table of non-operating fund occupation and other related party fund transactions for the first half of 2023, including detailed financial figures and explanations. It includes accounting subjects, balances, interest, and repayment amounts, and mentions a resignation of a board member. The document is a financial report covering a specific interim period (half-year) with substantive financial data and analysis. It is not an announcement or a brief summary but a detailed financial disclosure for the half-year period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 1854 characters, which is short but contains actual financial data, so it is not a report publication announcement or regulatory filing. Hence, the classification is IR with high confidence. H1 2023
2023-08-24 Chinese
第五届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of 新天地药业股份有限公司 regarding the approval of the 2023 semi-annual report, a special report on the use of raised funds, and the change of the auditing firm. It references the 2023 semi-annual report and other reports but does not contain the actual financial statements or detailed financial data itself. The document is relatively short (1552 characters) and mainly announces decisions and approvals made in a board meeting. It also directs readers to other filings on the official disclosure website for the full reports. Therefore, this document is not the semi-annual report itself but an announcement of board resolutions related to it. This fits best under Regulatory Filings (RNS), which is the fallback category for announcements and compliance documents that do not contain substantive financial data or full reports.
2023-08-24 Chinese
关于使用部分闲置募集资金购买结构性存款到期赎回并继续购买结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the use of idle raised funds to purchase structured deposits and related cash management activities. It includes details about investment amounts, expected returns, risk control measures, and approvals by the board and independent directors. The document is relatively short (3278 characters) and focuses on a specific financing/capital management activity rather than a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly/yearly results. The content fits best under Capital/Financing Update (CAP) as it updates on the company's use of capital and cash management activities involving raised funds.
2023-08-08 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.